Pharmaceutical

ADVANZ has entered into an arrangement agreement to acquire all of the issued and outstanding shares of Correvio Pharma.

ADVANZ Pharma (TSX:ADVZ) announced that through its subsidiary, the company has entered into an arrangement agreement to acquire all of the issued and outstanding shares of specialty pharmaceutical company Correvio Pharma (NASDAQ:CORV,TSX: CORV).

As quoted in the press release:

The acquisition is expected to have a total purchase price of approximately $76 million1, which includes the repayment of certain Correvio indebtedness, pursuant to a plan of arrangement (“Plan of Arrangement”) under the Canada Business Corporations Act.

Correvio is a Vancouver, Canada-based specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. Correvio’s commercial presence is focused on major European markets with a broader distribution network covering more than 60 countries worldwide. For the nine months ending September 30, 2019, Correvio generated revenue of approximately $21 million.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1798.67-8.20
Silver20.01-0.24
Copper3.62-0.09
Palladium1930.43+8.44
Platinum897.24+0.23
Oil104.92-0.84
Heating Oil3.830.00
Natural Gas5.67+0.25

DOWNLOAD FREE REPORTS

×